Glucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Glucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters

Published:2017-06-19 Issue:7 Volume:108 Page:1368-1377
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Kunimasa Kei¹,Nagano Tatsuya¹^ORCID,Shimono Yohei²,Dokuni Ryota¹,Kiriu Tatsunori¹,Tokunaga Shuntaro¹,Tamura Daisuke¹,Yamamoto Masatsugu¹,Tachihara Motoko¹,Kobayashi Kazuyuki¹,Satouchi Miyako³,Nishimura Yoshihiro¹

Affiliation:

1. Division of Respiratory Medicine; Kobe University Graduate School of Medicine; Kobe Japan

2. Division of Medical Oncology/Hematology Department of Internal Medicine; Kobe University Graduate School of Medicine; Kobe Japan

3. Department of Thoracic Oncology; Hyogo Cancer Center; Akashi Japan

Funder

Eli Lilly Japan

AstraZeneca

Novartis Pharma

Japan Society for the Promotion of Science

Kobe University School of Medicine Alumni Association

Shinryokukai General Incorporated Association

Hyogo Medical Association

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cas.13266/fullpdf

Reference51 articles.

1. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N Engl J Med,2010

2. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial;Mitsudomi;Lancet Oncol,2010

3. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol,2011

4. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy;Keedy;J Clin Oncol,2011

5. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer;Gainor;J Clin Oncol,2013

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diapause-like Drug-Tolerant Persister State: The Key to Nirvana Rebirth;Medicina;2024-01-28

2. Unveiling the role of cellular dormancy in cancer progression and recurrence;Current Opinion in Oncology;2024-01-03

3. Withaferin A: A Dietary Supplement with Promising Potential as an Anti-Tumor Therapeutic for Cancer Treatment - Pharmacology and Mechanisms;Drug Design, Development and Therapy;2023-09

4. Targeting drug‐tolerant cells: A promising strategy for overcoming acquired drug resistance in cancer cells;MedComm;2023-08-24

5. Withaferin A Increases the Effectiveness of Immune Checkpoint Blocker for the Treatment of Non-Small Cell Lung Cancer;Cancers;2023-06-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3